Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine

Antiviral Therapy

Volumn 15, Issue 6, 2010, Pages 817-829

  Kakuda, Thomas N ^a   Schöller Gyüre, Monika ^b   Hoetelmans, Richard M W ^b  

^a Tibotec Inc   (United States)

^b TIBOTEC BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; GLYCOPROTEIN P; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADD ON THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; P-GLYCOPROTEIN; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77957374853     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1652     Document Type: Review

References (70)

1. Seden K, Back D, Khoo S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother 2009; 64:5-8.
2. Robertson SM, Penzak SR, Pau AK. Drug interactions in the management of HIV infection. Expert Opin Pharmacother 2005; 6:233-253.
3. Robertson SM, Penzak SR, Pau AK. Drug interactions in the management of HIV infection: an update. Expert Opin Pharmacother 2007; 8:2947-2963.
4. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
5. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
6. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV- 1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
7. Trottier B, Mills A, Cahn P, et al. Durable efficacy and safety of etravirine (ETR; TMC125) in treatment-experienced, HIV-1-infected patients: pooled week 96 results from the Phase III DUET-1 and DUET-2 trials. 18th Annual Canadian Conference on HIV/AIDS Research. 23-26 April 2009, Vancouver, BC, Canada. Poster P148.
8. Kakuda TN, Wade JR, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther 2010; in press.
9. Schöller-Gyüre M, Boffito M, Pozniak AL, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy 2008; 28:1215-1222.
10. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71:115-121.
11. 14C-labelled TMC125 in healthy volunteers. 8th Workshop on Clinical Pharmacology of HIV therapy. 16-18 April 2007, Budapest, Hungary. Poster 78.
12. Schöller-Gyüre M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RM. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009; 48:561-574.
13. Kakuda TN, Schöller-Gyüre M, Workman C, et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther 2008; 13:655-661.
14. Kakuda TN, Schöller-Gyüre M, Woodfall B, et al. TMC125 in combination with other medications: summary of drug-drug interaction studies. 8th International Congress on Drug Therapy in HIV Infection. 12-16 November 2006, Glasgow, UK. Poster PL5.2.
15. Schöller-Gyüre M, Kakuda TN, Stevens T, et al. Effect of etravirine on cytochrome P450 isozymes assessed by the Cooperstown 5+1 cocktail. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Disease Society of America Meeting. 25-28 October 2008, Washington, DC, USA. Poster A-955.
16. Hartman NR, Yarchoan R, Pluda JM, et al. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990; 47:647-654. (Pubitemid 20190104)
17. Schöller-Gyüre M, Hoetelmans R, Bollen S, et al. No significant interaction between TMC125 and didanosine (ddl) in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HIV Therapy. 28-30 April 2005, Quebec City, QC, Canada. Poster 2.22.
18. Damle BD, Yan JH, Behr D, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol 2002; 42:419-427.
19. Hernández-Novoa B, Antela A, Gutiérrez C, et al. Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study. HIV Med 2008; 9:187-191.
20. Sánchez-Conde M, Palacios R, Sanz J, et al. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: the ELADI study. AIDS Res Hum Retroviruses 2007; 23:1237-1241.
21. López JC, Moreno S, Jiménez-Oñate F, Clotet B, Rubio F, Hernández-Quero J. A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART containing didanosine entericcoated capsules (FOODDIe Study). HIV Clin Trials 2006; 7:155-162.
22. Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51:3498-3504.
23. Kakuda TN, Schöller-Gyüre M, De Smedt G, et al. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med 2009; 10:173-181.
24. Kakuda TN, Schöller-Gyüre M, Peeters M, et al. Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-1-infected subjects. 9th International Workshop on Clinical Pharmacology of HIV Therapy. 7-9 April 2008, New Orleans, LA, USA. Poster P34.
25. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007; 320:72-80.
26. Baede P, Piscitelli S, Graham N, van't Klooster G. Drug interactions with TMC125, a potent next generation nonnucleoside reverse transcriptase inhibitor. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 27-30 September 2002, San Diego, CA, USA. Poster A-1827 3261.
27. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
28. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004; 24:1732-1747.
29. Schöller-Gyüre M, Woodfall B, De Marez T, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir. 8th International Congress on Drug Therapy in HIV Infection. 12-16 November 2006, Glasgow, UK. Poster P278.
30. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-2096.
31. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20:711-718.
32. Ray JE, Marriott D, Bloch MT, McLachlan AJ. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol 2005; 60:291-299.
33. trough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. New Microbiol 2005; 28:119-125.
34. Pellegrin I, Breilh D, Ragnaud JM, et al. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther 2006; 11:421-429.
35. Cleijsen RM, van de Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother 2007; 60:897-900.
36. Solas C, Colson P, Ravaux I, et al. The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV- 1-infected treatment- experienced patients. J Acquir Immune Defic Syndr 2008; 48:177-180.
37. Sekar V, Spinosa-Guzman S, Lefèbvre E, Hoetelmans R. Clinical pharmacology of TMC114 - a new HIV protease inhibitor. 16th International AIDS Conference. 13-18 August 2006, Toronto, ON, Canada. Poster TUPE0083.
38. Schöller-Gyüre M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and co-administered in HIV-negative volunteers. Antivir Ther 2007; 12:789-796.
39. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23:2289-2300.
40. DeJesus E, Lalezari J, Osiyemi O, et al. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV-1 infected adults. Antivir Ther 2010; 15:711-720.
41. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006; 45:137-168.
42. Schöller-Gyüre M, Woodfall B, Bollen S, et al. Pharmacokinetics of amprenavir and TMC125 in HIVinfected volunteers receiving TMC125 with fosamprenavir/ritonavir. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 27-30 September 2006, San Francisco, CA, USA. Poster A-370.
43. Molina JM, Ait-Khaled M, Rinaldi R, et al. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. J Antimicrob Chemother 2009; 64:398-410.
44. Chiba M, Hensleigh M, Lin JH. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol 1997; 53:1187-1195.
45. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome p450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42:52-60.
46. Piscitelli S, Baede P, van't Klooster G, et al. TMC125, a potent next generation NNRTI, does not alter lopinavir/ ritonavir pharmacokinetics in healthy volunteers. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 27-30 September 2002, San Diego, CA, USA. Poster A-1824.
47. Schöller-Gyüre M, Kakuda TN, Akuma SH, et al. Pharmacokinetic (PK) interaction between etravirine (ETR) and lopinavir/ritonavir (LPV/r). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 12-15 September 2009, San Francisco, CA, USA. Abstract A1-1298/31.
48. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001; 45:1086-1093.
49. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42:1048-1059.
50. Martin-Facklam M, Burhenne J, Ding R, et al. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. Br J Clin Pharmacol 2002; 53:576-581.
51. Justesen US, Fox Z, Pedersen C, et al. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. Basic Clin Pharmacol Toxicol 2007; 101:339-344.
52. Lötsch J, Harder S, Stürmer M, et al. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob Agents Chemother 2007; 51:3264-3272.
53. Mallolas J, Blanco J, Labarga P, et al. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. HIV Med 2007; 8:226-233.
54. Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 2007; 27:888-909.
55. Schöller-Gyüre M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy subjects. 13th Conference on Retroviruses and Opportunistic Infections. 5-9 February 2006, Denver, CO, USA. Poster 583.
56. Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI study 1182.51). J Acquir Immune Defic Syndr 2008; 47:429-440.
57. Harris M, Zala C, Woodfall B, et al. Pharmacokinetics (PK) and safety of adding TMC125 to stable regimens of saquinavir (SQV), lopinavir (LPV), ritonavir (RTV) and NRTIs in HIV+ adults. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Poster 575b.
58. Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005; 44:175-186.
59. Abel S, Russell D, Taylor-Worth RJ, Ridgeway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1:27-37. (Pubitemid 351366536)
60. Saltzman M, Rosenberg M, Kraan M, et al. Pharmacokinetics of vicriviroc administered alone or in combination with ritonavir or lopinavir/ritonavir. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract TuPe3.1B05.
61. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterisation of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49:4911-4919.
62. Davis J, Schöller-Gyüre M, Kakuda TN, et al. An open, randomized, two period, crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC125/darunavir/ritonavir on the steady state pharmacokinetics of oral maraviroc in healthy subjects. 11th European AIDS Conference. 24-27 October 2007, Madrid, Spain. Poster P4.3/02.
63. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti- AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657-1663.
64. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the HIV non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008; 52:4228-4232.
65. Ménard A, Solas C, Mokthari S, et al. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases. AIDS 2009; 27:869-871.
66. Wittkop L, Breilh D, Da Silva D, et al. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother 2009; 63:1251-1255.
67. Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs 2009; 10:190-200.
68. Ramanathan S, Kakuda TN, Mack R, West S, Kearney BP. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008; 13:1011-1017.
69. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 Infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133.
70. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multidrug-resistant virus: a Phase II randomized controlled trial. Lancet 2007; 369:1261-1269.